BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ma C, Lee JK, Mitra AR, Teriaky A, Choudhary D, Nguyen TM, Vande Casteele N, Khanna R, Panaccione R, Feagan BG, Jairath V. Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease. Aliment Pharmacol Ther 2019;50:5-23. [DOI: 10.1111/apt.15297] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 11.7] [Reference Citation Analysis]
Number Citing Articles
1 Atreya R, Peyrin-Biroulet L, Klymenko A, Augustyn M, Bakulin I, Slankamenac D, Miheller P, Gasbarrini A, Hébuterne X, Arnesson K, Knittel T, Kowalski J, Neurath MF, Sandborn WJ, Reinisch W; CONDUCT study group. Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial. Lancet Gastroenterol Hepatol 2020;5:1063-75. [PMID: 33031757 DOI: 10.1016/S2468-1253(20)30301-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
2 Ghoreschi K, Augustin M, Baraliakos X, Krönke G, Schneider M, Schreiber S, Schulze-Koops H, Zeißig S, Thaçi D. TYK2 inhibition and its potential in the treatment of chronic inflammatory immune diseases. J Dtsch Dermatol Ges 2021;19:1409-20. [PMID: 34580985 DOI: 10.1111/ddg.14585] [Reference Citation Analysis]
3 Lee J, Lemons N, Lorenze A, Chowdhary TS, Zinn Z, Gayam S. Management of cutaneous side effects of inflammatory bowel disease therapy: A dermatologic viewpoint. J Gastroenterol Hepatol 2021. [PMID: 34139789 DOI: 10.1111/jgh.15570] [Reference Citation Analysis]
4 Ghoreschi K, Augustin M, Baraliakos X, Krönke G, Schneider M, Schreiber S, Schulze-Koops H, Zeißig S, Thaçi D. TYK2-Inhibition: Potenzial bei der Behandlung chronisch-entzündlicher Immunerkrankungen. J Dtsch Dermatol Ges 2021;19:1409-20. [PMID: 34661350 DOI: 10.1111/ddg.14585_g] [Reference Citation Analysis]
5 Solimani F, Meier K, Ghoreschi K. Emerging Topical and Systemic JAK Inhibitors in Dermatology. Front Immunol 2019;10:2847. [PMID: 31849996 DOI: 10.3389/fimmu.2019.02847] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 17.3] [Reference Citation Analysis]
6 Lu Q, Yang M, Liang Y, Xu J, Xu H, Nie Y, Wang L, Yao J, Li D. Immunology of Inflammatory Bowel Disease: Molecular Mechanisms and Therapeutics. JIR 2022;Volume 15:1825-44. [DOI: 10.2147/jir.s353038] [Reference Citation Analysis]
7 Rowan C, Ungaro R, Mehandru S, Colombel JF. An overview of ozanimod as a therapeutic option for adults with moderate-to-severe active ulcerative colitis. Expert Opin Pharmacother 2022. [PMID: 35503955 DOI: 10.1080/14656566.2022.2071605] [Reference Citation Analysis]
8 Chebli JMF, Queiroz NSF, Damião AOMC, Chebli LA, Costa MHM, Parra RS. How to manage inflammatory bowel disease during the COVID-19 pandemic: A guide for the practicing clinician. World J Gastroenterol 2021; 27(11): 1022-1042 [PMID: 33776370 DOI: 10.3748/wjg.v27.i11.1022] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
9 Hmar EBL, Paul S, Boruah N, Sarkar P, Borah S, Sharma HK. Apprehending Ulcerative Colitis Management With Springing Up Therapeutic Approaches: Can Nanotechnology Play a Nascent Role? Curr Pathobiol Rep 2021;9:9-32. [DOI: 10.1007/s40139-020-00218-6] [Reference Citation Analysis]
10 Wieringa JW, van der Woude CJ. Effect of biologicals and JAK inhibitors during pregnancy on health-related outcomes in children of women with inflammatory bowel disease. Best Pract Res Clin Gastroenterol 2020;44-45:101665. [PMID: 32359679 DOI: 10.1016/j.bpg.2019.101665] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
11 Mainoli B, Hirota S, Edgington-mitchell LE, Lu C, Dufour A. Proteomics and Imaging in Crohn’s Disease: TAILS of Unlikely Allies. Trends in Pharmacological Sciences 2020;41:74-84. [DOI: 10.1016/j.tips.2019.11.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
12 Dolinger MT, Rolfes P, Phan BL, Dubinsky MC. Letter: tofacitinib use for biologic-refractory paediatric inflammatory bowel disease. Aliment Pharmacol Ther 2019;50:966-7. [DOI: 10.1111/apt.15496] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
13 Biemans VBC, Sleutjes JAM, de Vries AC, Bodelier AGL, Dijkstra G, Oldenburg B, Löwenberg M, van Bodegraven AA, van der Meulen-de Jong AE, de Boer NKH, Srivastava N, West RL, Römkens TEH, Horjus Talabur Horje CS, Jansen JM, van der Woude CJ, Hoekstra J, Weersma RK, van Schaik FDM, Hoentjen F, Pierik MJ; Dutch Initiative on Crohn and Colitis (ICC). Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry. Aliment Pharmacol Ther 2020;51:880-8. [PMID: 32237087 DOI: 10.1111/apt.15689] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 9.5] [Reference Citation Analysis]
14 Lortholary O, Fernandez-Ruiz M, Baddley JW, Manuel O, Mariette X, Winthrop KL. Infectious complications of rheumatoid arthritis and psoriatic arthritis during targeted and biological therapies: a viewpoint in 2020. Ann Rheum Dis 2020;79:1532-43. [PMID: 32963049 DOI: 10.1136/annrheumdis-2020-217092] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
15 Harris RE, Curtis L, Hegde V, Garrick V, Gervais L, Armstrong L, Delahunty C, Eccleston A, Al-Hourani G, Flynn DM, Merrick V, Barclay AR, Tayler R, Hansen R, Russell RK. A Decade of Varicella Screening Within a Paediatric Inflammatory Bowel Disease Population. J Crohns Colitis 2020;14:608-16. [PMID: 31889176 DOI: 10.1093/ecco-jcc/jjz207] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Troncone E, Marafini I, Del Vecchio Blanco G, Di Grazia A, Monteleone G. Novel Therapeutic Options for People with Ulcerative Colitis: An Update on Recent Developments with Janus Kinase (JAK) Inhibitors. Clin Exp Gastroenterol 2020;13:131-9. [PMID: 32440190 DOI: 10.2147/CEG.S208020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
17 Wu G, Yang Y, Liu M, Wang Y, Guo Q. Systematic Review and Network Meta-Analysis: Comparative Efficacy and Safety of Biosimilars, Biologics and JAK1 Inhibitors for Active Crohn Disease. Front Pharmacol 2021;12:655865. [PMID: 33935772 DOI: 10.3389/fphar.2021.655865] [Reference Citation Analysis]
18 Scribano ML. Why Do Immunosuppressed Patients with Inflammatory Bowel Disease Not Seem to Be at a Higher Risk of COVID-19? Dig Dis Sci. 2020;Online ahead of print. [PMID: 33073335 DOI: 10.1007/s10620-020-06624-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
19 Hernandez-rocha C, Vande Casteele N. JAK inhibitors: current position in treatment strategies for use in inflammatory bowel disease. Current Opinion in Pharmacology 2020;55:99-109. [DOI: 10.1016/j.coph.2020.10.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 D'Amico F, Peyrin-Biroulet L, Danese S. JAK or GUT Selectivity: Tipping the Balance for Efficacy and Safety in Ulcerative Colitis. J Crohns Colitis 2020;14:1185-7. [PMID: 32579170 DOI: 10.1093/ecco-jcc/jjaa074] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Hu X, Li J, Fu M, Zhao X, Wang W. The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther 2021;6:402. [PMID: 34824210 DOI: 10.1038/s41392-021-00791-1] [Reference Citation Analysis]
22 Wang L, Hu Y, Song B, Xiong Y, Wang J, Chen D. Targeting JAK/STAT signaling pathways in treatment of inflammatory bowel disease. Inflamm Res 2021;70:753-64. [PMID: 34212215 DOI: 10.1007/s00011-021-01482-x] [Reference Citation Analysis]
23 Salas A, Hernandez-Rocha C, Duijvestein M, Faubion W, McGovern D, Vermeire S, Vetrano S, Vande Casteele N. JAK-STAT pathway targeting for the treatment of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 2020;17:323-37. [PMID: 32203403 DOI: 10.1038/s41575-020-0273-0] [Cited by in Crossref: 63] [Cited by in F6Publishing: 67] [Article Influence: 31.5] [Reference Citation Analysis]
24 Kaymak T, Kaya B, Wuggenig P, Nuciforo S, Göldi A, Oswald F, Roux J, Noti M, Melhem H, Hruz P, Niess JH; Swiss EoE Cohort Study Group (SEECS). IL-20 subfamily cytokines impair the oesophageal epithelial barrier by diminishing filaggrin in eosinophilic oesophagitis. Gut 2022:gutjnl-2022-327166. [PMID: 35613844 DOI: 10.1136/gutjnl-2022-327166] [Reference Citation Analysis]
25 McLornan DP, Pope JE, Gotlib J, Harrison CN. Current and future status of JAK inhibitors. Lancet 2021;398:803-16. [PMID: 34454676 DOI: 10.1016/S0140-6736(21)00438-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Chimenti MS, Conigliaro P, Biancone L, Perricone R. Update on the therapeutic management of patients with either psoriatic arthritis or ulcerative colitis: focus on the JAK inhibitor tofacitinib. Ther Adv Musculoskelet Dis 2021;13:1759720X20977777. [PMID: 33680096 DOI: 10.1177/1759720X20977777] [Reference Citation Analysis]
27 Papa A, Tursi A, Danese S, Rapaccini G, Gasbarrini A, Papa V. Venous Thromboembolism in Patients with Inflammatory Bowel Disease: The Role of Pharmacological Therapy and Surgery. J Clin Med 2020;9:E2115. [PMID: 32635542 DOI: 10.3390/jcm9072115] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Ghoreschi K, Balato A, Enerbäck C, Sabat R. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet 2021;397:754-66. [PMID: 33515492 DOI: 10.1016/S0140-6736(21)00184-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 13.0] [Reference Citation Analysis]
29 Gonciarz M, Pawlak-Buś K, Leszczyński P, Owczarek W. TYK2 as a therapeutic target in the treatment of autoimmune and inflammatory diseases. Immunotherapy 2021;13:1135-50. [PMID: 34235974 DOI: 10.2217/imt-2021-0096] [Reference Citation Analysis]
30 Allocca M, Chaparro M, Gonzalez HA, Bosca-Watts MM, Palmela C, D'Amico F, Zacharopoulou E, Kopylov U, Ellul P, Bamias G, Ntelis V, Lahat A, Mantzaris GJ, Papaconstantinou I, Katsanos K, Uspenskaya Y, Christodoulou D, Ben Horin S, Peyrin-Biroulet L, Torres J, Sebastian S, Gisbert JP, Danese S, Fiorino G. Patients with Inflammatory Bowel Disease Are Not at Increased Risk of COVID-19: A Large Multinational Cohort Study. J Clin Med. 2020;9. [PMID: 33142843 DOI: 10.3390/jcm9113533] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
31 Wang L, Ping X, Chen W, Xing W. Performance of Janus kinase inhibitors in psoriatic arthritis with axial involvement in indirect comparison with ankylosing spondylitis: a retrospective analysis from pooled data. Clin Rheumatol 2021;40:1725-37. [PMID: 33067773 DOI: 10.1007/s10067-020-05442-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Garrido I, Lopes S, Macedo G. Hit the Road JAK! The Role of New Oral Treatment in Inflammatory Bowel Disease. Inflamm Bowel Dis 2021:izab037. [PMID: 33742651 DOI: 10.1093/ibd/izab037] [Reference Citation Analysis]
33 Lefevre PLC, Vande Casteele N. Clinical Pharmacology of Janus Kinase Inhibitors in Inflammatory Bowel Disease. J Crohns Colitis 2020;14:S725-36. [PMID: 32160283 DOI: 10.1093/ecco-jcc/jjaa014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
34 Damsky W, Peterson D, Ramseier J, Al-Bawardy B, Chun H, Proctor D, Strand V, Flavell RA, King B. The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases. J Allergy Clin Immunol 2021;147:814-26. [PMID: 33129886 DOI: 10.1016/j.jaci.2020.10.022] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
35 Moore H, Dubes L, Fusillo S, Baldassano R, Stein R. Tofacitinib Therapy in Children and Young Adults With Pediatric-onset Medically Refractory Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2021;73:e57-62. [PMID: 34091545 DOI: 10.1097/MPG.0000000000003190] [Reference Citation Analysis]
36 Danese S, Roda G, Peyrin-Biroulet L. Evolving therapeutic goals in ulcerative colitis: towards disease clearance.Nat Rev Gastroenterol Hepatol. 2020;17:1-2. [PMID: 31520081 DOI: 10.1038/s41575-019-0211-1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 14.5] [Reference Citation Analysis]
37 Moon SY, Kim KD, Yoo J, Lee JH, Hwangbo C. Phytochemicals Targeting JAK-STAT Pathways in Inflammatory Bowel Disease: Insights from Animal Models. Molecules 2021;26:2824. [PMID: 34068714 DOI: 10.3390/molecules26092824] [Reference Citation Analysis]
38 Al-Bawardy B, Shivashankar R, Proctor DD. Novel and Emerging Therapies for Inflammatory Bowel Disease. Front Pharmacol 2021;12:651415. [PMID: 33935763 DOI: 10.3389/fphar.2021.651415] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
39 Dagnew AF, Rausch D, Hervé C, Zahaf T, Levin MJ, Schuind A; ZOE-50/70 study group. Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials. Rheumatology (Oxford) 2021;60:1226-33. [PMID: 32910152 DOI: 10.1093/rheumatology/keaa424] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
40 Li Y, Yao C, Xiong Q, Xie F, Luo L, Li T, Feng P. Network meta‐analysis on efficacy and safety of different Janus kinase inhibitors for ulcerative colitis. Clinical Pharmacy Therapeu. [DOI: 10.1111/jcpt.13622] [Reference Citation Analysis]
41 Wang Y, Wan Z, Jin R, Xu T, Ouyang Y, Wang B, Ruan G, Bai X. Tofacitinib for extraintestinal manifestations of inflammatory bowel disease: A literature review. International Immunopharmacology 2022;105:108517. [DOI: 10.1016/j.intimp.2022.108517] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Brenner EJ, Ungaro RC, Gearry RB, Kaplan GG, Kissous-Hunt M, Lewis JD, Ng SC, Rahier J-F, Reinisch W, Ruemmele FM, Steinwurz F, Underwood FE, Zhang X, Colombel J-F, Kappelman MD. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. Gastroenterology. 2020;159:481-491.e483. [PMID: 32425234 DOI: 10.1053/j.gastro.2020.05.032] [Cited by in Crossref: 265] [Cited by in F6Publishing: 269] [Article Influence: 132.5] [Reference Citation Analysis]
43 Spiewak TA, Patel A. User's Guide to JAK Inhibitors in Inflammatory Bowel Disease. Current Research in Pharmacology and Drug Discovery 2022. [DOI: 10.1016/j.crphar.2022.100096] [Reference Citation Analysis]